Cure JM: Research Grants

Cure JM: Research Grants

Status: ACTIVE
Funder: Cure JM Foundation
Amount: US $75,000 - US $150,000
Last Updated: March 15, 2026

Summary

Cure JM offers grant funding for research into juvenile myositis, a rare autoimmune disease affecting children. Established in 2003, the foundation aims to enhance care and find better treatments. In 2025, it will provide research grants up to $75K per year for two years, prioritizing applicants with significant protected research time. Eligible candidates include Ph.D. or M.D. holders affiliated with accredited institutions. Collaborative proposals are encouraged, focusing on innovative therapies and clinical protocols.

Overview

Cure JM offers grant funding for clinicians and researchers who are working to improve juvenile myositis care and research. Cure JM is a 501(c)(3) non-profit organization established in 2003. The mission of Cure JM is to find better treatments and a cure for Juvenile Myositis and improve the lives of families affected by JM. Approximately 2 to 4 children in a million in the United States are diagnosed with JM each year. In 2025, Cure JM has committed to fund new research grants up to $75K/year for up to 2 years with preference for individuals who have at least 25% protected research time from their institution.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website. Applicants must hold a Ph. D. or M.D. degree or equivalent and work in an accredited medical school, university, hospital, or research institute, which must agree to supply the clinical and/or laboratory facilities. The foundation strongly encourages collaborations from two or more institutions that bring together a spectrum of expertise. Grant applications are called for across programs relating to all aspects of; basic research, clinical trials, translational studies, diagnosis, and clinical care of juvenile myositis. A pertinent but not exhaustive list of priorities includes:Conducting analyses on samples and/or data available from innovative treatment clinical studies.Collaboration with pharmaceutical companies or other research organizations that are developing new therapies that may have utility in the treatment of juvenile myositis. The collaboration may comprise the generation of clinical protocols for new treatments and a defined route to funding a clinical study. Such proposals should include solid evidence of access to the therapy being proposed for investigation.Clinical protocols for repurposed drugs for the treatment of juvenile myositis. Such proposals should include solid evidence of access to the therapy being proposed for investigation and a defined route to funding a clinical study.Investigations of in vitro or in vivo models of juvenile myositis with the objective of the development of new therapies.Novel diagnostic strategies, including the development of biomarkers.All aspects of clinical care, spanning mental health and consensus treatment protocols.